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Abstract
The cytosolic glutathione S-transferase (GST) enzymes serve as ideal biomarkers of organ
damage as they exhibit many of the required characteristics, i.e. specific localisation, high
cytosolic concentration and relatively short half-life. The role of GSTs as early indicators of
organ damage is applicable to both human and animal models. Because of the regio-specific
localisation of the different isoforms of GST in liver and kidney, simultaneous monitoring of
classes of GSTs in biological matrices permits the identification of specific areas of damage
within a particular organ. Immunoassays have been developed which quantify canine aGST
and rodent mGST (Yb1). The immunoassays are solid phase EIAs, where GST in the sample
or standard is captured by a specific anti-GST antibody coated onto the solid phase. After
washing, a specific enzyme-labelled IgG conjugate is added which binds to the captured
GST. After a further washing step, substrate is added and a colour developed. The
absorbance is measured on an ELISA plate reader and is directly proportional to the amount
of GST present in the sample. The assays are performed at room temperature and can be
completed within 3 h. The immunoassays are specific for each GST and have a range of
0–100 mg:l. A range of assay parameters were investigated to validate the EIAs for GST
detection. The assays are sensitive and reproducible. CV for inter- and intra-assay variation
were below 9% for Yb1 assay and below 20% for the canine aGST EIA. Recovery of spiked
GST over the standard curve range was 102 and 99%, respectively. No prozone effect was
observed and samples exhibited linearity of dilution in both assays. Validation has shown
that using these enzyme immunoassay, Yb1 and canine aGST can be measured accurately
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and precisely in biological matrices, tissue homogenates and cell lines and that changes in
GST levels can be detected. The use of these assays have important applications in both in
vitro and in vivo toxicity studies, where GSTs serve as sensitive marker of hepatocellular and
renal cell integrity. © 1998 Elsevier Science Ireland Ltd. All rights reserved.
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1. Introduction
The glutathione S-transferases (GSTs) are a family of cytosolic enzymes involved
in the detoxification of a range of xenobiotic compounds by conjugation to
glutathione. The enzymes consist of homo- and heterodimers grouped into species-
independent families: alpha (a), pi (p), mu (m) and theta (u) as well as a
microsomal trimeric enzyme [1].
In man, a-glutathione S-transferase (aGST) is the predominant GST isoform in
the liver. The uniform hepatic distribution together with relatively high hepatic
levels and a short plasma half-life (90 min) mean that this enzyme is more
sensitive than the aminotransferases as an indicator of hepatocyte status following
transplantation, drug-induced liver damage, hepatitis C infection and a-interferon
therapy [2–4]. It has recently been reported that monitoring aGST in the first 3
post-operative months after transplantation resulted in improved patient care and
reduced mortality and morbidity [5]. Transplant recipients who had aGST reported
to the ward, had fewer biopsies, a lower incidence of more severe rejection and
fewer episodes of infection. Patients also had shorter stays in hospital post-opera-
tively and better graft survival up to 100 days post-operation.
A similarly unique regio-specific distribution of aGST and pGST occurs in the
kidney. aGST is located primarily in the proximal tubules, whereas pGST is
present mainly in the distal tubule region of the nephron [6]. A number of different
groups have been able to identify specific damage to the proximal or distal tubules
in the kidney by monitoring urinary GST. One study looked at kidney damage
resulting from the administration of the anaesthetic sevoflurane [7]. The authors
were able to distinguish between proximal and distal tubular damage by the
simultaneous analysis of urinary a and pGST. In another study, psoriasis patients
who developed renal impairment while receiving Cyclosporin A (a known nephro-
toxin which targets the proximal tubules of the kidney) also showed significantly
increased urinary aGST prior to any increase in creatinine or glomular filtration
rate (GFR) [8].
Because of the world-wide shortage of organs for transplantation, there is an
increasing demand for alternative sources of suitable grafts. Xenotransplantation
has been suggested as one possible solution, but many practical as well as ethical
problems have been associated with this area. Another option is the use of organs
from non-heart beating donors (NHB). aGST has been successfully used to
monitor the viability of NHB donor kidneys prior to transplantation [9]. These
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organs are obtained from NHB donors after final and irreversible cardiac arrest
and undergo a period of warm ischemia. The duration of this period of ischemia
is critical in determining the outcome of transplantation, as increased ischemia
times may result in non-viable grafts. Since ischemia predominantly damages cells
in the proximal tubules [10], the monitoring of aGST can provide valuable
information on the status of the organs prior to transplantation. There was a
strong correlation between the release of aGST and the period of warm ischemia
where high levels of aGST were associated with increased warm ischemia times
and poor graft function. Thus, by monitoring aGST in the kidney perfusate
during machine preservation, the functional outcome of NHB donor grafts can
be predicted before transplantation, assisting in the selection of viable organs for
transplantation. Levels of aGST can now be used to define reliable safety mar-
gins for viability of NHB kidneys.
The main function of the GST family of enzymes is the detoxification of
xenobiotics. The protection imparted by these enzymes on the cells against poten-
tially harmful electrophilic compounds is essential in the maintenance of normal
healthy processes. However, GSTs have also been implicated in other areas,
namely as indicators of malignant transformation and acquired resistance of cells
to chemotheraputic drugs [11].
There have been numerous publications on the increased expression of GST, in
particular pGST, in the malignant transformation of a variety of cells and tissues
including bladder [12], head and neck [13], colon [14], ovarian [15,16] and renal
cell [17]. Associated with this increased expression of GST is the enhanced
detoxification capability of the cell. This has serious implications for drug ther-
apy as acquired resistance can seriously limit the effectiveness of clinically impor-
tant anti-cancer drugs.
The distribution of GSTs in animal models follows a similar pattern to that in
humans and thus they fulfil similar roles as early indicators of organ damage.
aGST has been shown to be a more sensitive marker than the transaminases in
the assessment of hepatocellular damage in isolated perfused rat livers [18]. In
rats, mGST (Yb1) has been located to the distal convoluted tubule of the rat
kidney, whereas aGST (YaYc) has been found in the proximal as well as the
distal tubule [19].
Compound A, a degradation product of the anaesthetic sevoflurane, was
shown to cause an increase in urinary aGST in rats [20]. This increase was
mirrored by an increase in proximal tubular cell necrosis, identified by histologi-
cal examination. The measurement of Yb1 in urine has been shown to be an
excellent indicator of nephrotoxicity or kidney damage caused by cisplatin [21].
Other nephrotoxic agents have also been shown to increase kidney Yb1 concen-
tration [22,23].
GSTs have been identified in a number of canine tissues, including liver [24]
and lens [25]. As in man, the liver has a high concentration of aGST and canine
liver cytosolic GSTs have been purified, characterised and found to contain class
m, a and p subunits, together with a possible u class subunit [26].
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Since enzyme activity assays do not readily facilitate differentiation between the
various GST isoenzymes, the development of immunoassays can offer a simple
alternative for the specific detection of GSTs. This will allow more accurate
monitoring of in vitro or in vivo toxicological studies involving rats or dogs as
animal models to predict drug toxicity in humans.
2. Materials and methods
2.1. Purification of GST
Yb1 GST was purified from rat liver by affinity chromatography according to the
method of Hayes [27], with the exception of S-hexyl GSH-sepharose being used
instead of GSH-sepharose. The procedure involved homogenisation of the tissue,
centrifugation and chromatography using S-hexyl GSH-sepharose. Purity was
established by reducing SDS-PAGE [28] and no significant cross-reactivity was
observed with the a or p isoforms of rat GST using Western blot analysis [29].
aGST was purified from canine liver obtained from a beagle dog, essentially by
GSH-sepharose affinity chromatographic techniques [30]. The liver was ho-
mogenised and after centrifugation applied to a GSH affinity column. Purity was
established by reducing SDS-PAGE [28]. Using Western blot analysis [29], minimal
cross-reactivity was evident for canine m or pGST isoforms respectively. Protein
quantitation was by Coomassie protein assay and also by absorbance measure-
ments at 280 nm.
2.2. Antibody production and purification
New Zealand White rabbits were immunised subcutaneously (s.c.) with purified
GST, emulsified in Freunds Adjuvant. When the titre was sufficient, the serum was
collected and tested for anti-GST specificity by dot blot. IgG present was extracted
using Protein A sepharose chromatography. Purified IgG was used for 96-well plate
coating and conjugation to horseradish peroxidase, (Yb1 assay) and for conjuga-
tion to N-hydroxy-succinimido-biotin (canine aGST assay). A murine monoclonal
IgG directed against human aGST exhibited 100% cross-reactivity with canine
aGST and was used for 96-well plate coating.
3. GST enzyme immunoassay
Biotrin Canine aGST EIA and Rat Yb1 EIA are quantitative enzyme im-
munoassays. Both EIA procedures are based on the sequential addition of sample,
conjugate and substrate to 96-well plates pre-coated with anti-GST-IgG. The
resultant colour intensity is directly proportional to the amount of GST in the
sample (Fig. 2). The assay ranges are 0–100 mg:l.
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4. Assay validation
The following parameters were evaluated in order to validate the EIAs for GST
detection: (1) reproducibility (inter- and intra-assay variation); (2) assay sensitivity;
(3) parallelism; (4) sample spiking and recovery.
5. Results
Antisera raised against both Yb1 and canine aGST was checked for cross-reac-
tivity with other isoforms of rodent and canine GST respectively by Western blot
analysis and EIA. Fig. 1A shows Western blot analysis of Yb1, YaYc and Yp, as
well as rat liver and kidney homogenates using anti-Yb1 antisera. No significant
cross-reactivity was observed with any other major isoform of rodent GST. In the
Yb1 immunoassay, no significant cross-reactivity was detected with Yp or YaYc.
Fig. 1B similarly shows the specificity of the monoclonal anti-aGST antibody
used for plate coating in the canine aGST EIA. No cross-reactivity was observed
Fig. 1. (A) Immunoblot analysis of rat GST isoenzymes. Evaluation of the specificity of anti-Yb1
antisera used in the Rat Yb1 EIA. Tracks 2–4 contain 1 mg of GST. (B) Western blots following
SDS:PAGE of total canine GST (track 1) and purified Canine aGST (track 2). Immunoblots were
probed with monoclonal IgG[anti mGST]human, (blot 1), monoclonal IgG [anti-aGST]human, (blot 2) and
polyclonal IgG[anti-pGST]human (blot 3).
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Fig. 2. Schematic diagram of the Rat Yb1 EIA and the canine aGST EIA.
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Table 1
Determination of the sensitivity of the rat Yb1 EIA and the canine aGST EIA
GST concentration (mg:l)aMean O.D. S.D.
0.125 0.006 0.232Yb1
2.0940.085Canine aGST 0.152
Sensitivity was determined by assaying the zero calibrator on 30 occasions. The concentration corre-
sponding to the mean O.D. value plus 2 S.D. was deemed to be the limit of detection. The sensitivity
of the Yb1 assay was 0.2 and 2.1 mg:l for the canine aGST assay in the microwell.
a A450:630 nm converted to [GST] mg:l from calibration curve.
with any other isoform of canine GST. In the immunoassay, no significant
cross-reactivity was detected with canine p or m.
The assay sensitivity (i.e. the lowest concentration distinguishable from zero) was
determined from the analysis of 30 negative samples in the assay. The concentration
corresponding to the optical density (O.D.) of the mean of the 30 negatives plus
two standard deviations (S.D.) was deemed to be the lower limit of detection of the
assay. For the Yb1 EIA, the sensitivity in the microwell was 0.2 mg:l, corresponding
to 2.0 mg:l in a sample diluted 1:10. In the canine aGST EIA, the sensitivity was
determined to be 2.1 mg:l in the microwell, corresponding to an initial sample
concentration of 10.5 mg:l when assayed at a 1:5 dilution (Table 1).
Precision was investigated as inter- and intra-assay reproducibility. Inter-assay
reproducibility was determined based on the analysis of three samples at concentra-
tions spanning the range of the standard curve, assayed in duplicate, in ten separate
assays. Intra-assay reproducibility was calculated from the analysis of three samples
at varying concentrations, assayed in ten replicates in the same assay.
In the Yb1 assay, the coefficient of variation (CV) for the mean inter-assay
reproducibility over the range of the standard curve was 8.5% (range: 8.3–8.8%)
(Table 2A), while the CV for the mean intra-assay reproducibility was 6.2% (range:
5.1–7.1%) (Table 2B). In the canine aGST EIA, the CV for the mean inter-assay
Table 2
(A) Inter- and (B) intra- assay variation in the rat Yb1 EIA and the canine aGST EIA
Canine aGST EIARat Yb1 EIA
A
1 2 3Sample A B C
1063.2755.727.856.1Mean (mg:l) 25.17.4
0.62 2.2 4.7S.D. 5.04 64.6947.95
6.35 6.088.3%CV 8.8 8.4 18.16
B
1 2 3Sample A B C
8.3 1345.414.851.2 683.631.4Mean (mg:l)
55.40.4 3.1S.D. 3.62.1 133.6
21.27.16.65.1%CV 8.1 9.9
Samples were assayed according to the kit instructions.
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Table 3
Sample recovery:linearity of dilution
Dilution (aGST) mg:l
Canine serumSample diluent
443.61 (95.9%)497.41 (107.5%)1:5
472.05 (102.0%)484.68 (104.8%)1:10
1:20 470.88 (101.8%) 464.54 (100.4%)
418.32 (90.4%)1:40 425.72 (92.0%)
Canine serum and assay sample diluent were spiked with purified aGST and each assayed at four
different dilutions.
reproducibility was 11.5% (range: 6.7–21.2%) (Table 2A), while the CV for the
mean intra-assay reproducibility was 9% (range: 5.1–17.7%) (Table 2B).
Tables 3 and 4 illustrate sample recovery:linearity of dilution in the canine GST
assay, whereby the recovery of purified aGST spiked into canine serum was
compared to that for assay sample diluent. Mean recovery was 99% (Table 3).
Linearity of dilution of canine aGST was observed in other biological matrices
including serum, urine and cell culture media (Table 4), confirming the compatibil-
ity of these matrices in the immunoassay.
The mean recovery of spiked Yb1 into rat urine over a range of concentrations
from was 102% (Table 5)
Linearity of dilution for Yb1 was observed in tissue homogenates and urine
samples (Table 6) and no prozone effect was observed up to levels of 3.5 g:l.
The normal range for Yb1 in Sprague Dawley and Wistar rats was established by
assaying normal urine samples from 30 Sprague Dawley and 23 Wistar rats. It
appears that the normal range of Yb1 differs between different strains of rat. For
Sprague Dawley rats, the range was 5–65 mg:l, while for Wistar rats a range of
3–30 mg:l was observed. There does not however appear to be any difference
between the levels of Yb1 in urine from female and male rats.
The utility of the canine aGST EIA in measuring hepatic damage has been
investigated (Fig. 3). Following warm ischemic damage to the liver in adult beagle
dogs, serum aGST levels were measured and compared to the traditional transam-
inases (GOT and GPT). GST levels showed an initial peak greater than either of
Table 4
Detection and quantitation of canine aGST which was spiked into a variety of matrices including
serum, urine and tissue culture medium (M.E.M. and TC-100)
Human urineM.E.M.Canine serumSample diluentDilution TC-100
382.89 365.82 433.63400.381:5 348.80
386.43 379.091:10 435.06 437.73 421.33
389.32386.96462.40399.10 394.901:20
435.48 440.44 416.40 376.721:40 406.24
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Table 5
Recovery of high and low concentrations of Yb1 spiked into samples containing various concentra-
tions of Yb1
Basal level (mg:l Yb1) Final concentration (mg:l) % RecoverySample
102.756.41 91.831
104.12 106.0 141.57
109.3107.253 68.11
111.7670.78 110.94
98.35 17.5 115.6
100.8124.523.56
103.33.2 100.17
8 91.515.7 105.9
High samples were spiked with 30 mg:l Yb1, and low samples were spiked with 100 mg:l Yb1. The mean
recovery was 102%.
the other enzymes, and also exhibited a more rapid normalisation than the
transaminases [31]. This pattern is similar to that observed in studies of liver
damage in humans. The canine aGST EIA was also used to quantify aGST as a
percentage of total soluble protein in canine liver cytosol (3.1%), and in the MDCK
cell line (3.87 ng:106 cells).
6. Conclusions
Enzyme immunoassays have been developed for the quantitative determination
of canine aGST and rodent mGST (Yb1) in various biological matrices [31,32]. The
assays are performed at room temperature and can be completed within 3 h.
Multiple sample analysis is possible. Validation studies have shown that canine
aGST and rodent Yb1 can be accurately and precisely determined using the
respective enzyme immunoassay and that changes in the levels of GSTs are
detectable.
GST Yb1 has been located to the distal convoluted tubule of the rat kidney,
whereas YaYc (aGST) has been found in the proximal as well as the distal tubule
[19]. Any event which precipitates distal tubule damage in the rat kidney may cause
an increase in urinary Yb1 levels, and a number of nephrotoxic agents have been
Table 6
Linearity of dilution of samples in the rat Yb1 EIA
Sample 2 (mg:l)Intestine homogenate (mg:l) Sample 3 (mg:l)Dilution factor
222.11:10 606.5 115.6
247.4 587.9 129.41:20
306.0 647.9 129.61:40
Samples were serially diluted 1:10, 1:20 and 1:40 and assayed.
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Fig. 3. Serum profile of aGST, sGOT and sGPT in adult female beagle dogs (8–12.8 kg) following
induced warm ischemia by total hepatic vascular exclusion, showing a rapid normalisation of [aGST].
shown to increase urinary Yb1 concentrations [22,23]. The measurement of Yb1 in
urine has been predicted as an excellent indicator of nephrotoxicity or kidney
damage caused by cisplatin [21]. Thus, by the simultaneous measurement of YaYc
and Yb1, it may be possible to identify and differentiate between damage to the
proximal and distal tubules in the rat kidney.
Elevated levels of canine aGST, present after hepatic injury, are detectable
demonstrating the utility of the technique for monitoring in vivo hepatic status.
With the concerted efforts to find alternative methods to animal testing for new
drugs, the focus is turning to in vitro model systems. The ability to study the effects
of novel compounds on primary cells, cell lines or tissue slices grown in static or
perfusion cultures will play a pivotal role in these new testing methods. Hepatocytes
and renal cells in particular will form the basis of studying the hepato- and
nephro-toxic properties of new pharmaceuticals. Because of the specific localisation
of GSTs in both of these cell types, the monitoring of GSTs will provide critical
information on the status of the cells in any culture system. Indeed studies have
already shown that GSTs can be used as markers of cell viability of human liver
and kidney slices in an in vitro system, as well as markers for drug-induced toxicity
[33,34].
Another important implication of these tests is the ability to distinguish between
organ damage in two inter-connected animal model systems. Because of the high
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level of specificity of the rodent and porcine EIAs, no cross-reactivity was observed
between the same class of GSTs from different animal species. For example,
bioartificial livers (BAL) containing isolated porcine hepatocytes were connected to
rats with liver ischemia [35]. By simultaneously monitoring plasma for rodent and
porcine aGST, it was possible to differentiate between damage caused to the rodent
liver and to the porcine hepatocytes in the BAL. While rodent aGST levels peaked
at 6 h of liver ischemia and gradually decreased at 14 h, no increase in porcine
aGST was detected during this time. It was therefore possible to determine that the
hepatocytes in the BAL were not effected by the damage caused to the rodent liver
and the BAL was capable of maintaining pig hepatocyte integrity in vivo over a
period of 14 h.
The necessity of animal toxicity testing of new therapeutics and drugs requires
the availability of validated, reliable, easy to use and sensitive tests. GSTs have
proved to be sensitive markers of organ and tissue damage caused by a wide range
of harmful substances. The easy availability of rapid, easy to use, reliable tests to
monitor GSTs in a variety of biological matrices, from a range of animal models
facilitates the study of both in vivo and in vitro systems.
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